Concomitant use of steroids or phototherapy with chlormethine gel among patients with mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study

被引：0
|
作者：
Querfeld, Christiane [1 ]
Turini, Marco [2 ]
Gor, Deval [3 ]
Angello, James T. [2 ]
Pashos, Chris [3 ]
Kim, Ellen J. [4 ]
机构：
[1] City Hope Comprehens Canc Ctr, Div Dermatol, Duarte, CA USA
[2] Helsinn Healthcare SA, Lugano, Switzerland
[3] Genesis Res LLC, Hoboken, NJ USA
[4] Univ Penn, Philadelphia, PA 19104 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2021年 / 156卷
关键词：
Chlormethine gel; registry; observational study;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tre-P-01
引用
收藏
页码：S44 / S45
页数：2
相关论文
共 40 条
  • [31] HEALTH-RELATED QUALITY OF LIFE ASSOCIATED WITH MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA PATIENTS: DETERMINATION OF UTILITY VALUES FROM A UK-BASED CLINICIAN QUESTIONNAIRE
    Scarisbrick, J.
    Schmidt, F.
    Turini, M. M.
    D'agostino, P.
    Thornton, S.
    Evans, J.
    Ader, J.
    van Hest, N.
    Brazier, J. E.
    VALUE IN HEALTH, 2020, 23 : S715 - S715
  • [32] Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015
    Ling, You-Li
    Huang, Xingyue
    Mitri, Ghaith
    Lovelace, Belinda
    An Pham
    Knobler, Robert
    Li, Xiaocong
    Gao, Xin
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (01) : 91 - 98
  • [33] Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Lavin, Leore
    Dusza, Stephen
    Geller, Shamir
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2025, 145 (01)
  • [34] Development of a patient-centric patient reported outcome instrument to assess the quality of life of patients living with mycosis fungoides/sezary syndrome-type cutaneous T cell lymphoma (MF/SS-CTCL)
    Braverman, Julia
    Towner, Auriell N.
    Raja, Priya L.
    Harrington, Magdalena
    Simacek, Kristina F.
    QUALITY OF LIFE RESEARCH, 2015, 24 : 89 - 89
  • [35] Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States
    Barta, Stefan K.
    Liu, Nicholas
    DerSarkissian, Maral
    Chang, Rose
    Ye, Mingchen
    Duh, Mei Sheng
    Surinach, Andy
    Fanale, Michelle A.
    Yu, Kristina S.
    BLOOD, 2022, 140 : 5167 - 5169
  • [36] Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019
    Girardi, Michael
    Carlson, Kacie
    Huang, Xingyue
    Corman, Shelby L.
    Edmundson, Patrick
    Schmier, Jordana
    Kale, Hrishikesh P.
    Raina, Rutika
    Foss, Francine
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [37] COMBINED RESULTS FROM THE PHASE 3 MAVORIC STUDY: PRIMARY SAFETY AND EFFICACY, WITH POST HOC ANALYSES ON EFFICACY BY PRIOR SYSTEMIC THERAPY, LONG TERM EXPOSURE OF MOGAMULIZUMAB (MOGA) IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL), AND EFFICACY, AND SAFETY IN EARLY STAGE MYCOSIS FUNGOIDES (MF) PATIENTS
    Zinzani, P. L.
    Kim, Y.
    Bagot, M.
    Scarisbrick, J.
    Geskin, L.
    Ortiz-Romero, P.
    HAEMATOLOGICA, 2019, 104 : 46 - 46
  • [38] Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
    Scarisbrick, Julia
    Horwitz, Steven M.
    Prince, H. Miles
    Whittaker, Sean
    Duvic, Madeleine
    Kim, Youn H.
    Quaglino, Pietro
    Zinzani, Pier Luigi
    Bechter, Oliver
    Eradat, Herbert
    Pinter-Brown, Lauren
    Akilov, Oleg
    Geskin, Larisa
    Sanches, Jose
    Ortiz-Romero, Pablo
    Lisano, Julie
    Brown, Lisa
    Bunn, Veronica
    Little, Meredith
    Dummer, Reinhard
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S31 - S31
  • [39] Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study
    Shouse, Geoffrey
    Kaempf, Andy
    Gordon, Max J.
    Yashar, David
    Sigmund, Audrey M.
    Smilnak, Gordon
    Bair, Steven M.
    Mian, Agrima
    Fitzgerald, Lindsey A.
    Bajwa, Amneet
    Jaglowski, Samantha
    Bailey, Neil
    Shadman, Mazyar
    Patel, Krish
    Stephens, Deborah M.
    Kamdar, Manali
    Hill, Brian T.
    Gauthier, Jordan
    Karmali, Reem
    Nastoupil, Loretta J.
    Kittai, Adam S.
    Danilov, Alexey, V
    BLOOD, 2022, 140 : 2048 - 2050
  • [40] HEALTHCARE RESOURCE USE (HCRU) AND ASSOCIATED COSTS AMONG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH CAR-T CELLS IN FRANCE - A REAL-WORLD STUDY USING DATA FROM PMSI
    Di Blasi, R.
    Thieblemont, C.
    Haioun, C.
    Sala, Sackmann L.
    Mayaud, A. C.
    Diez-Andreu, P.
    Bugnard, F.
    Goguillot, M.
    Finzi, J.
    Chillotti, L.
    Benard, S.
    VALUE IN HEALTH, 2022, 25 (12) : S79 - S80
1234